Icotrokinra not checked

Janssen Research & Development, LLC · JNJ-77242113 · PN-21235

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 3 trial completes
Trials
10 active
16 in total · 9 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Plaque Psoriasis (5 trials), Arthritis, Psoriatic (2 trials), Generalized Pustular Psoriasis, Erythrodermic Psoriasis, Colitis, Ulcerative, Crohn Disease
Main trialPhase 3
“The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).”In the company’s words, NCT06095102 on ClinicalTrials.gov
Other names
JNJ-77242113 · PN-21235 · PN-235

Other drugs for Plaque Psoriasis

All 41 drugs for Plaque Psoriasis

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 19 Jun 2024 A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Phase 3Active, not recruiting 29 Jul 2024 A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Phase 3Active, not recruiting 17 Sep 2024 A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Phase 3Active, not recruiting 15 Nov 2024 A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Phase 3Active, not recruiting 14 Jan 2025 A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Phase 3Active, not recruiting 17 Nov 2025 A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Phase 3Active, not recruiting 25 May 2026 A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Phase 3Active, not recruiting 10 Feb 2027 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Phase 3Active, not recruiting 14 Jan 2028 A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2/3Recruiting 19 Sep 2028 A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Phase 2Completed 15 Dec 2022 A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Phase 2Completed 23 Mar 2023 A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Phase 2Completed 29 Sep 2023 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
Phase 2Completed 26 Sep 2024 A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 1Completed 28 Sep 2022 A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants
Phase 1Completed 7 Apr 2023 A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Icotrokinra

Following is part of Solo: you see every change to Icotrokinra the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in